MOTS-c research connects a short peptide to mitochondrial signalling and metabolic adaptation. The papers often combine several kinds of evidence: molecular experiments, treated mice and measurements in people. Understanding which part supports a particular statement is more useful than collecting every result under a broad performance or longevity heading.
Start with the origin of the name
Lee and colleagues reported MOTS-c in 2015 from a short open reading frame within the mitochondrial 12S rRNA region. The name refers to that genomic origin. Their paper identified a 16-amino-acid signalling peptide.Lee and colleagues — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis (opens in a new tab)
Mitochondrial-derived is an identity and discovery description. It should not be read as a guarantee that an externally supplied preparation reaches every mitochondrion or restores mitochondrial function in any setting.
The supplied 10 mg and 20 mg reports describe a lyophilised, mitochondrial-derived 16-residue peptide. Both state a match to a qualified reference by LC-HRMS, but neither prints the complete amino-acid sequence.Supplied MOTS-c 10 mg report (opens in a new tab)Supplied MOTS-c 20 mg report (opens in a new tab)
A literature comparison should therefore preserve two records: the molecule defined in the publication and the reference identity asserted for the supplied sample. Connecting them requires the underlying reference specification, rather than relying only on the shared product name.
Read the metabolic mechanism at the level tested
The discovery study linked MOTS-c effects to folate and purine metabolism and AMPK activation. It also reported protection against age-related and high-fat-diet-associated insulin resistance in mice.Lee and colleagues — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis (opens in a new tab)
That describes a pathway relationship and animal outcomes. It does not establish that MOTS-c binds directly to AMPK as a conventional receptor agonist, nor does it establish treatment efficacy for human diabetes.
For any proposed mechanism, ask where the causal experiment sits. A change in a pathway marker, a perturbation that weakens an effect and direct molecular binding are different observations. A useful summary names the observation actually made.
Separate endogenous human responses from mouse treatment
Reynolds and colleagues’ 2021 study measured MOTS-c around exercise in ten healthy young men. Endogenous levels rose in skeletal muscle and circulation. The human component did not administer MOTS-c to demonstrate improved performance.Reynolds and colleagues — MOTS-c, exercise and age-dependent physical decline (opens in a new tab)
Other components of that paper administered the peptide to mice and reported changes in physical-performance measures. In young mice, rotarod and running findings did not mean that every tested outcome improved: grip strength and the reported memory assessment did not show the same benefit.Reynolds and colleagues — MOTS-c, exercise and age-dependent physical decline (opens in a new tab)
| Observation | Question it addresses |
|---|---|
| Human levels around exercise | Whether the endogenous signal changes with the exercise condition |
| Performance after mouse treatment | Whether the tested intervention changes a particular animal outcome |
The two lines can motivate further investigation together. They cannot be joined into an unperformed human treatment trial. Likewise, a healthspan description should retain the functional measurements used rather than becoming a promise of longer human life.
Build a useful MOTS-c evidence record
Sort a new finding by what was changed and what was measured. Was the peptide administered, its expression manipulated, or its natural concentration simply observed? Then record the species, tissue and functional endpoint.
This is especially helpful when a paper contains both cell and whole-animal work. A cellular stress response can support a mechanistic hypothesis without accounting for every behavioural or metabolic result.
The most useful next evidence would resolve a specific remaining question: identity of the preparation, reproducibility in another model, a causal pathway step or a properly controlled human outcome. A longer list of loosely related mitochondrial findings would not resolve those gaps.
Analytical purity and content belong in the material record. They do not measure physical capacity, insulin sensitivity or lifespan, and should not be presented as confirmation of those biological claims.
Sources and further detail
- Lee and colleagues — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis (opens in a new tab)
Original 2015 abstract and indexed publisher results read. Genomic origin, length, pathway context and mouse findings retained; no direct AMPK-binding claim.
- Reynolds and colleagues — MOTS-c, exercise and age-dependent physical decline (opens in a new tab)
Author-hosted original 2021 paper read for human observation versus mouse intervention and endpoint differences. No human performance or longevity treatment claim.
- Supplied MOTS-c 10 mg report (opens in a new tab)
Complete supplied PDF read. Reference-based identity statement transcribed; no independent authentication or full printed sequence claimed.
- Supplied MOTS-c 20 mg report (opens in a new tab)
Complete supplied PDF read to compare the identity description across sizes, not to infer equivalent biological effects.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.